PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.

Immunotherapy can become a crucial therapeutic option to improve prognosis for lung cancer patients. First clinical trials with therapies targeting the programmed cell death receptor PD-1 and its ligand PD-L1 have shown promising results in several solid tumors. However, in lung cancer the diagnosti...

Full description

Bibliographic Details
Main Authors: Lars Henning Schmidt, Andreas Kümmel, Dennis Görlich, Michael Mohr, Sebastian Bröckling, Jan Henrik Mikesch, Inga Grünewald, Alessandro Marra, Anne M Schultheis, Eva Wardelmann, Carsten Müller-Tidow, Tilmann Spieker, Christoph Schliemann, Wolfgang E Berdel, Rainer Wiewrodt, Wolfgang Hartmann
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4552388?pdf=render

Internet

http://europepmc.org/articles/PMC4552388?pdf=render

Similar Items